148 related articles for article (PubMed ID: 24923294)
1. Asymmetric dimethylarginine and progression of chronic kidney disease: a one-year follow-up study.
Eiselt J; Rajdl D; Racek J; Vostrý M; Rulcová K; Wirth J
Kidney Blood Press Res; 2014; 39(1):50-7. PubMed ID: 24923294
[TBL] [Abstract][Full Text] [Related]
2. Association between estimated glomerular filtration rate (eGFR) and asymmetric dimethylarginine (ADMA) concentrations among the elderly in a rural community: a cross-sectional study.
Choi HR; Lee SW; Jeon DH; Hur NW; Youm Y; Kim HC
BMC Geriatr; 2019 Dec; 19(1):370. PubMed ID: 31870320
[TBL] [Abstract][Full Text] [Related]
3. Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease.
Emrich IE; Zawada AM; Martens-Lobenhoffer J; Fliser D; Wagenpfeil S; Heine GH; Bode-Böger SM
Clin Res Cardiol; 2018 Mar; 107(3):201-213. PubMed ID: 29101459
[TBL] [Abstract][Full Text] [Related]
4. Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients.
Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Ueda Y; Suzuki T; Yamada S; Takeuchi M; Fukami K; Ueda S; Adachi H; Matsui T; Okuda S; Yamagishi S
Metabolism; 2009 Nov; 58(11):1624-8. PubMed ID: 19604520
[TBL] [Abstract][Full Text] [Related]
5. Arginine, dimethylated arginine and homoarginine in relation to cardiovascular risk in patients with moderate chronic kidney disease.
Hov GG; Aasarød KI; Sagen E; Åsberg A
Clin Biochem; 2015 Jul; 48(10-11):646-51. PubMed ID: 25828044
[TBL] [Abstract][Full Text] [Related]
6. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach.
Ravani P; Tripepi G; Malberti F; Testa S; Mallamaci F; Zoccali C
J Am Soc Nephrol; 2005 Aug; 16(8):2449-55. PubMed ID: 15944335
[TBL] [Abstract][Full Text] [Related]
7. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study.
Fliser D; Kronenberg F; Kielstein JT; Morath C; Bode-Böger SM; Haller H; Ritz E
J Am Soc Nephrol; 2005 Aug; 16(8):2456-61. PubMed ID: 15930091
[TBL] [Abstract][Full Text] [Related]
8. Oxidative stress and asymmetric dimethylarginine is independently associated with carotid intima media thickness in peritoneal dialysis patients.
Kocak H; Gumuslu S; Ermis C; Mahsereci E; Sahin E; Gocmen AY; Ersoy F; Suleymanlar G; Yakupoglu G; Tuncer M
Am J Nephrol; 2008; 28(1):91-6. PubMed ID: 17914250
[TBL] [Abstract][Full Text] [Related]
9. Circulating angiopoietin-2 levels increase with progress of chronic kidney disease.
David S; Kümpers P; Lukasz A; Fliser D; Martens-Lobenhoffer J; Bode-Böger SM; Kliem V; Haller H; Kielstein JT
Nephrol Dial Transplant; 2010 Aug; 25(8):2571-6. PubMed ID: 20179005
[TBL] [Abstract][Full Text] [Related]
10. Plasma asymmetric dimethylarginine and its association with some of cardiovascular disease risk factors in chronic kidney disease.
Quoc Hoang TA; Tam V; Thang HV
Med J Malaysia; 2019 Jun; 74(3):209-214. PubMed ID: 31256175
[TBL] [Abstract][Full Text] [Related]
11. Asymmetric dimethylarginine and clinical outcomes in chronic kidney disease.
Lu TM; Chung MY; Lin CC; Hsu CP; Lin SJ
Clin J Am Soc Nephrol; 2011 Jul; 6(7):1566-72. PubMed ID: 21642363
[TBL] [Abstract][Full Text] [Related]
12. Synergism between asymmetric dimethylarginine (ADMA) and a genetic marker of uric acid in CKD progression.
Testa A; Mallamaci F; Leonardis D; Spoto B; Pisano A; Sanguedolce MC; Tripepi G; Zoccali C;
Nutr Metab Cardiovasc Dis; 2015 Feb; 25(2):167-72. PubMed ID: 25435339
[TBL] [Abstract][Full Text] [Related]
13. Measuring asymmetric dimethylarginine (ADMA) in CKD: a comparison between enzyme-linked immunosorbent assay and liquid chromatography-electrospray tandem mass spectrometry.
Pecchini P; Malberti F; Mieth M; Quinn R; Tripepi G; Mallamaci F; Maas R; Zoccali C; Ravani P
J Nephrol; 2012; 25(6):1016-22. PubMed ID: 22322824
[TBL] [Abstract][Full Text] [Related]
14. [Significance of the factors of hypoxia and endothelial dysfunction in kidney injury in the presence of obesity].
Galiamov MG; Saginova EA; Severova MM; Samokhodskaia LM; Krasnova TN; Sholomova VI; Sorokin IuD; Mukhin NA
Ter Arkh; 2013; 85(6):31-7. PubMed ID: 23866596
[TBL] [Abstract][Full Text] [Related]
15. Competitive interaction between fibroblast growth factor 23 and asymmetric dimethylarginine in patients with CKD.
Tripepi G; Kollerits B; Leonardis D; Yilmaz MI; Postorino M; Fliser D; Mallamaci F; Kronenberg F; Zoccali C
J Am Soc Nephrol; 2015 Apr; 26(4):935-44. PubMed ID: 25150156
[TBL] [Abstract][Full Text] [Related]
16. Association of asymmetric dimethylarginine with severity of kidney injury and decline in kidney function in IgA nephropathy.
Fujimi-Hayashida A; Ueda S; Yamagishi S; Kaida Y; Ando R; Nakayama Y; Fukami K; Okuda S
Am J Nephrol; 2011; 33(1):1-6. PubMed ID: 21109733
[TBL] [Abstract][Full Text] [Related]
17. Time course of asymmetric dimethylarginine and symmetric dimethylarginine levels after successful renal transplantation.
Claes KJ; Bammens B; Kuypers DR; Meijers B; Naesens M; Sprangers B; Vanrenterghem Y; Lerut E; de Loor H; Evenepoel P
Nephrol Dial Transplant; 2014 Oct; 29(10):1965-72. PubMed ID: 24957811
[TBL] [Abstract][Full Text] [Related]
18. Arginine/asymmetric dimethylarginine ratio and cardiovascular risk factors in patients with predialytic chronic kidney disease.
Hov GG; Sagen E; Hatlen G; Bigonah A; Åsberg A; Aasarød K
Clin Biochem; 2011 Jun; 44(8-9):642-6. PubMed ID: 21406191
[TBL] [Abstract][Full Text] [Related]
19. Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease.
Wang J; Sim AS; Wang XL; Salonikas C; Naidoo D; Wilcken DE
Atherosclerosis; 2006 Feb; 184(2):383-8. PubMed ID: 15939423
[TBL] [Abstract][Full Text] [Related]
20. Accumulation of uraemic toxins is reflected only partially by estimated GFR in paediatric patients with chronic kidney disease.
Snauwaert E; Van Biesen W; Raes A; Holvoet E; Glorieux G; Van Hoeck K; Van Dyck M; Godefroid N; Vanholder R; Roels S; Walle JV; Eloot S
Pediatr Nephrol; 2018 Feb; 33(2):315-323. PubMed ID: 28939943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
